Early-access Avacopan in Real-world ANCA-associated Vasculitis
Evaluating Clinical Practice of Early Access Avacopan Treatment for ANCA-associated Vasculitis in European Countries
Leiden University Medical Center
100 participants
Nov 1, 2023
OBSERVATIONAL
Conditions
Summary
The current study proposal aims to investigate the clinical practice variation of the initial use of avacopan for AAV patients in Europe. The study will describe patient characteristics and organ-specific clinical benefit of avacopan treatment in a unique, first-experience cohort of AAV patients. By studying the clinical practice variation of first-experience avacopan treatment, this study will be uniquely positioned to identify pivotal issues on the real-life implementation of avacopan treatment. These observational data can ultimately serve to address current knowledge gaps on avacopan treatment in AAV patients, improve the care and drug-access for AAV patients with avacopan treatment and generate new areas of research.
Eligibility
Inclusion Criteria3
- Established diagnosis of GPA or MPA
- Treatment (initiation) with avacopan
- Informed consent for use of medical data
Exclusion Criteria2
- If there is no AAV disease activity present that can be supported by an objectifiable clinical measure or assessment
- If a subject is below 16 years old
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06794827